1415689-63-2

Upstream product

• 1415689-47-2 methyl 2,3-dimethoxy-6-(methoxymethyl)-4-methylbenzoate 
• 32263-14-2 4-hydroxy-3-methoxy-5-methylbenzaldehyde 
• 1415689-52-9 methyl 6-(chloromethyl)-2,3-dimethoxy-4-methylbenzoate 
• 80547-80-4 3,4-dimethoxy-5-methylbenzaldehyde 
• 1415689-57-4 2-(3-chloro-4-fluorobenzyl)-6,7-dimethoxy-5-methylisoindolin-1-one 
• 80547-79-1 (3,4-dimethoxy-5-methylphenyl)methanol 
• 1415689-43-8 1,2-dimethoxy-5-(methoxymethyl)-3-methylbenzene 

Downstream Products

• 1415689-81-4 2-(3-chloro-4-fluorobenzyl)-6,7-dimethoxy-N,N,5-trimethyl-1-oxoisoindoline-4-sulfonamide 
• 1421423-81-5 2-(3-chloro-4-fluorobenzyl)-5,6,7-trimethoxy-N,N-dimethyl-1-oxoisoindoline-4-sulfonamide 
• 1415689-37-0 C₁₈H₁₈ClFN₂O₅S 

Relevant academic research and scientific papers

HIV INTEGRASE INHIBITORY OXOISOINDOLINE SULFONAMIDES

Novel oxoisoindoline sulfonamide integrase inhibitors are useful to inhibit HIV activity, and are therefore suitable for treatment or prophylaxis of HIV infection, for example in the treatment or prevention of AIDS. In particular embodiments, the inhibito

6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 integrase inhibitors

Although an extensive body of scientific and patent literature exists describing the development of HIV-1 integrase (IN) inhibitors, Merck's raltegravir and Gilead's elvitegravir remain the only IN inhibitors FDA-approved for the treatment of AIDS. The em